Healthnewsreviews blog: The marketing of anemia drugs - a story we shouldn't forget (including comments) Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Wednesday, May 16, 2012

Healthnewsreviews blog: The marketing of anemia drugs - a story we shouldn't forget (including comments)



The marketing of anemia drugs - a story we shouldn't forget

 "In an opinion piece on TheScientist.com, Daniel W. Coyne writes, “Amgen’s incomplete report on an early major trial of epoetin misled the medical community about the anemia drug’s risks and benefits—and helped make Amgen rich.”
In the book, “How We Do Harm,” Otis Brawley, MD, chief medical and scientific officer of the American Cancer Society, writes quite a bit about hemoglobin-building drugs.  He discusses:.....

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.